Hervolution Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hervolution Therapeutics - overview
Established
2011
Location
Frederiksberg, -, Denmark
Primary Industry
Biotechnology
About
Founded in 2011 and based in Frederiksberg, Denmark, Hervolution Therapeutics formerly known as, InProTher Aps operates as a biotechnology company that engages in developing immunotherapies for patients with cancer. As of 2023, Jordi Naval serves as the CEO of the company. In May 2023, InProTher Aps raised seed funding from the European Innovation Council. The round was part of a larger EUR 6 million seed and venture debt round.
In December 2024, Hervolution Therapeutics raised USD 11. 7 million in series A funding from new investor Serum Institute of India Pvt. Ltd. , with participation from returning investor European Innovation Council.
Other unspecified investors also participated in the round. The company is developing immunotherapies that overcome the limits of cancer vaccines by targeting HERV tumour antigens with a method that stimulates both the humoral and cellular immune systems. The firm's primary product, IPT001, mutates the ISD domain within the HERV immunogen. InProTher distributes its modified immunogen as cancer vaccines using adenoviral and RNA vectors.
InProTher's technique of action focuses on the enhanced immune system's ability to resist viruses via antibodies, CD8+ T cells, and CD4+ T cells. The organization plans to use the May 2023 funding for the advancement of its research and development.
Current Investors
European Innovation Council, Serum Institute of India Pvt. Ltd.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.hervolutiontx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Hervolution Therapeutics - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (231,578) | - | - | - | 9,814 | 15,668 | (62,288) | (7,086,407) | (8,542,642) | (5,207,419) | - | - | - |
| Operating Income (USD) | (231,578) | - | - | - | 9,814 | 15,668 | (67,856) | (5,994,132) | (7,640,635) | (5,207,419) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (174,484) | (104,389) | 11,373 | (40,223) | 9,814 | 15,365 | (65,072) | (7,348,600) | (9,207,671) | (3,738,644) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Hervolution Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.